Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G P Reynolds

Showing results (21-30 of 187) with videos related to

Pageof 19
Sort By:
European Psychiatry : the Journal of the Association of European Psychiatrists|August 25, 2009
Receptor mechanisms of antipsychotic drug atypicalityG P Reynolds
Drugs|January 1, 1996
The importance of dopamine D4 receptors in the action and development of antipsychotic agentsG P Reynolds
Modern Problems of Pharmacopsychiatry|January 1, 1983
Assessment of MAO inhibitors using postmortem human brain tissue: biochemical and therapeutic implicationsG P Reynolds, P Riederer
Neuroscience Letters|March 21, 1998
Increased peripheral benzodiazepine binding sites in the brain of patients with Huntington's diseaseK Messmer, G P Reynolds
Journal of Neural Transmission|January 1, 1989
[3H] GBR 12935 binding to the dopamine uptake site in post-mortem brain tissue in schizophreniaC Czudek, G P Reynolds
European Journal of Pharmacology|January 5, 2000
Agonist-stimulated GTPgamma[35S] binding to 5-HT(1A) receptors in human post-mortem brainJ Elliott, G P Reynolds
Neuroscience Letters|May 4, 2001
Increased density of glutamate/N-methyl-D-aspartate receptors in superior temporal cortex in schizophreniaS Nudmamud, G P Reynolds
Lancet (London, England)|December 14, 1985
Alzheimer-like brain monoamine deficits in adults with Down's syndromeG P Reynolds, H Godridge
British Journal of Clinical Pharmacology|January 1, 1980
Deprenyl is a selective inhibitor of brain MAO-B in the long-term treatment of Parkinsons's diseaseP Reiderer, G P Reynolds
Psychopharmacology Bulletin|January 1, 1988
Status of the dopaminergic system in post-mortem brain in schizophreniaG P Reynolds, C Czudek
Pageof 19

Showing results (21-30 of 187) with videos related to

Sort By:
Pageof 19
European Psychiatry : the Journal of the Association of European Psychiatrists|August 25, 2009
Receptor mechanisms of antipsychotic drug atypicalityG P Reynolds
Drugs|January 1, 1996
The importance of dopamine D4 receptors in the action and development of antipsychotic agentsG P Reynolds
Modern Problems of Pharmacopsychiatry|January 1, 1983
Assessment of MAO inhibitors using postmortem human brain tissue: biochemical and therapeutic implicationsG P Reynolds, P Riederer
Neuroscience Letters|March 21, 1998
Increased peripheral benzodiazepine binding sites in the brain of patients with Huntington's diseaseK Messmer, G P Reynolds
Journal of Neural Transmission|January 1, 1989
[3H] GBR 12935 binding to the dopamine uptake site in post-mortem brain tissue in schizophreniaC Czudek, G P Reynolds
European Journal of Pharmacology|January 5, 2000
Agonist-stimulated GTPgamma[35S] binding to 5-HT(1A) receptors in human post-mortem brainJ Elliott, G P Reynolds
Neuroscience Letters|May 4, 2001
Increased density of glutamate/N-methyl-D-aspartate receptors in superior temporal cortex in schizophreniaS Nudmamud, G P Reynolds
Lancet (London, England)|December 14, 1985
Alzheimer-like brain monoamine deficits in adults with Down's syndromeG P Reynolds, H Godridge
British Journal of Clinical Pharmacology|January 1, 1980
Deprenyl is a selective inhibitor of brain MAO-B in the long-term treatment of Parkinsons's diseaseP Reiderer, G P Reynolds
Psychopharmacology Bulletin|January 1, 1988
Status of the dopaminergic system in post-mortem brain in schizophreniaG P Reynolds, C Czudek
Pageof 19